Neuron myelination is accelerated by Bruton's tyrosine kinase inhibition via microglial extracellular vesicles
Related Experiment Video
Updated: Oct 31, 2026
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
Published on: June 17, 2025
Matteo Tartaglia1,2, Arianna Ioni1, Mariassunta De Luca1
1Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
Introduction:
The altered myelin repair observed in demyelinating diseases such as multiple sclerosis (MS) potentially exposes axons to various stressors, with consequent neurodegeneration. Preclinical evidence has demonstrated that Bruton's tyrosine kinase inhibitors (BTKi), such as ibrutinib, delay MS progression by acting on myeloid cells.
Methods:
We investigated the effects of ibrutinib on remyelination using a novel in vitro model of spinal cord neurons derived from postnatal mice.
Results:
We demonstrated that (1) spinal cord neuron cells represent a suitable model for investigating myelination following L‑α‑lysophosphatidylcholine (LPC) treatment; (2) ibrutinib induces remyelination and reduces stathmin‑1 expression in spinal cord cultures; and (3) ibrutinib reduces the inflammatory phenotype of microglia‑like BV2 cells, thereby modulating the expression of miR‑223 in extracellular vesicles (EVs).
Discussion:
Altogether, these data pave the way for a better understanding of the mechanisms underlying remyelination following ibrutinib treatment and support the hypothesis that EV‑derived microglial cells play a key role.
